Skip to main content
. 2010 May 6;2010:964597. doi: 10.1155/2010/964597

Table 1.

Ten patients were identified in the study. They are listed from 1 to 10 and referenced this way throughout the paper. DSRS: distal splenorenal shunt; PSRS: proximal splenorenal shunt; PCS: portocaval shunt; PV: portal vein; UTI: urinary tract infection. *MELD score 1 month post shunt. **MELD score 1 month and 13 years post shunt.

Patient no. Age Primary disease Shunt type MELD/PELD score pre- and postop Primary reason for shunt Complications 30-day mortality Graft patency Followup years
EHPH group

1 17 PV Thrombosis DSRS Variceal Bleeding None None Patent 7.08 Alive

2 17 PV Thrombosis PSRS Variceal Bleeding None None Thrombosed 1.08 Alive

IHPH group

3 17 Congenital Hepatic Fibrosis DSRS 6 6 Variceal Bleeding None None Patent 7.4 Alive

4 5 Congenital Hepatic Fibrosis Side-to-side PCS 7 8 Variceal Bleeding UTI, central-line infection None Patent 0.92 Alive

5 19 Cystic Fibrosis DSRS 7 11 Variceal Bleeding None None Patent 0.5 Died

6 15 Congenital Hepatic Fibrosis PSRS 20 21 Variceal Bleeding Bleeding Fundal Varices 10 days postop Negative reexploration Received liver transplant 13 months later post PSS 1.08 Alive

7 18 Hepatic Vein Thrombosis Side-to-side PCS 18 12* Liver Dysfunction None None Shunt occluded at 3 months. Received liver txp 6 months later 12.8 Died

8 18 Hepatic Vein Thrombosis PCSH-graft 18 13** Liver Dysfunction None None Patent 13.16 Alive

9 15 Congenital Hepatic Fibrosis DSRS 7 7 Hypersplenism None None Patent 6.5 Alive

10 10 Congenital Hepatic Fibrosis Side-to-side PCS 8 11 Hypersplenism None None Patent 1.92 Alive